Posts filtered by tags: Drug Pricing[x]


 

Despite Drug Industry Claims, Higher List Prices Do Mean Higher Out-of-Pocket Costs for Many Patients

New research suggests that as the list price of brand name drugs rise, so do out-of-pocket medical costs for these drugs—at least for some patients. This is counter to a common industry claim that patients aren’t affected by list price increases. The study found a link between list prices rising and out-of-pocket…Read more...
Tags: Health, Science, Medicare, Martin Shkreli, Daraprim, Turing Pharmaceuticals, Pharmacy, Pharmaceutical Industry, Drug Pricing, Prescription drug, Health Sciences, U S Healthcare, Healthcare Reform In The United States, Pharmaceuticals Policy, Health Medical Pharma, Benjamin Rome


We could know if a vaccine works this month

Welcome to Business Insider's daily healthcare newsletter, your daily dose of pharma, biotech, and healthcare news. Subscribe here to get this newsletter in your inbox every weekday. Hollis Johnson/Business Insider Hello,...And suddenly it's October! If anyone has good inspiration for a festive, spooky Twitter name, please let me know. Today in healthcare news: 7 events to keep an eye on in the vaccine race this month, an investigation shows how pharma execs raised drug prices, and get y...
Tags: Europe, UK, US, Trends, House, Healthcare, Astrazeneca, Pfizer, Vaccines, Donald Trump, Reuters, Celgene, Bristol Myers Squibb, Teva, McNamee Getty, Drug Pricing


Astellas Bets On Gene Therapy With $3B Audentes Acquisition Offer

Japanese drug giant Astellas Pharma announced late Monday it has agreed to buy Audentes Therapeutics, which is developing gene therapies for rare neuromuscular diseases.It’s an all-cash deal worth $3 billion, with the Astellas offer of $60 per share representing a 110 percent premium to Audentes’ (NASDAQ: BOLD) share price of $28.61 apiece at market close Monday. The agreement is the latest big bet by a major pharmaceutical company on gene therapy, which aims to provide long-lasting, if not per...
Tags: Deals, San Francisco, Trends, Startup, M&a, Mergers, Antitrust, Fda, National, Biotech, Buyout, Acquisition, Spark, Life Sciences, Audentes Therapeutics, Rare Disease


Bio Roundup: CRISPR Babies, Blood Diseases, Big Cancer Nod & More

This was one of those weeks when the world seemed to slip into a new era with no going back. A Chinese researcher, He Jiankui, claimed he helped bring to life two genetically engineered babies, twin girls with a gene disabled to make them immune to HIV infection. Even though the technology He used—in vitro fertilization, CRISPR-Cas9 gene editing, deep sequencing—has been in place for some time to attempt the creation of a gene-altered human, the scientific world hoped for three years that self-...
Tags: Deals, Hong Kong, Scandal, White House, China, Trends, Investment, Fail, People, Vc, Leukemia, Lung Cancer, Ireland, Venture Capital, Genomics, Private Equity


Bio Roundup: Prices on TV, Novartis Hearts Radio, Warp Drive’s End

Two new battlegrounds emerged this week in the nation’s ongoing drug pricing debate. The first involved television: The federal government hopes that blaring prices in TV ads will essentially pressure drug makers into lowering them, and the pharma lobby fired back. The second centered around a group of pricey new migraine drugs: The nation’s largest drug-pricing middleman used a familiar muscle-flexing tactic to grab some discounts, and kicked one drug in the class to the curb as a result.Elsew...
Tags: Deals, Startups, Microsoft, Breast Cancer, Drugs, Trends, Merck, Vc, Humira, Adalimumab, Prostate Cancer, Paul Allen, Astrazeneca, National, Novartis, Pfizer


Bio Roundup: Drug Prices, CRISPR Caveats, Rubius IPO Pop & More

After nearly two years of all smoke, no fire around President Trump’s promise to curtail drug prices, there’s finally some glimmer of action. Pfizer said last week it would halt its price hikes, and Novartis and Merck took similar actions this week. But we still don’t know the details of the administration’s drug-pricing policy, if there is one beyond the blueprint released in May. And we don’t know if the moves by Pfizer, Novartis, and Merck are just for optics, or indicative of deeper industr...
Tags: Deals, Dna, Trends, Merck, Bill Gates, Fda, National, Novartis, Pfizer, Allergan, Biotech, Roundups, Verge Genomics, Life Sciences, Martin Shkreli, Trump


Bio Roundup: ASCO Abstracts, Migraine Drug Prices & “Blueprint” Fallout

There’s nothing abstract about a 20 percent jump in a company’s stock price. But yeah, that happened to Loxo Oncology when it released data previews for its American Society for Clinical Oncology presentations; the meeting starts in two weeks in Chicago. Wednesday was ASCO abstract day, and we’ll round up the headliners below, all with caveats that these early peeks are not peer-reviewed and could be updated in a couple weeks. It’s even worth asking whether they’re worth writing about at ...
Tags: Deals, Trends, Chicago, Fda, National, Novartis, Pfizer, Roundups, Illumina, Life Sciences, Trump, Syndax Pharmaceuticals, Celgene, Amgen, ASCO, Broad Institute


Bio Roundup: Hope for Lungs, Bradner’s Complaint, FDA Nods & More

The biggest news this week was in oncology, hands down. Merck showed that its immunotherapy pembrolizumab (Keytruda) might become a common option for many patients newly diagnosed with advanced lung cancer, but the bigger picture is that the field is moving fast. While pembrolizumab notched the headline-grabbing data, others are also working to develop options for various subsets of patients. Who will be able to afford all these options? We explored that question in our coverage. The pric...
Tags: Amazon, Security, Hong Kong, Budget, Email, Review, Senate, White House, Ipo, Cancer, New York City, Trends, Supply Chain, Investment, Merck, Bloomberg


Xconomy Roadmap 2018: Top 15 Innovation Areas to Watch

View the Slideshow With the first quarter in the books, it’s time to step back and lay out Xconomy’s editorial map for the rest of the year. As readers know, we strive to cover a wide range of innovation sectors, from tech and life sciences to healthcare and education—all with a mix of on-the-ground reporting, daily news stories, in-depth features and analysis, and events and conferences. It’s a daunting task, made more daunting by today’s short news cycles and media saturation on certai...
Tags: Security, Startups, Transportation, Leadership, Hardware, Education, Privacy, Finance, Cancer, Trends, Strategy, E-commerce, It, Cybersecurity, Vc, Artificial Intelligence


How Much Is Too Much For a Life-Saving Drug?

When it comes to breakthrough therapies, sometimes it seems as though each new potentially life-saving drug comes with a price tag more expensive than the last. Novartis’ Kymriah, which became the first to win FDA approval for a groundbreaking new type of cancer treatment called CAR-T last year, priced its therapy at…Read more...
Tags: Science, Genetics, Fda, Novartis, Gene Therapy, Drug Pricing, Car T


Bio Roundup: Tax Cuts, a Funding Rush, Hemophilia Questions & More

In the penultimate week before the end-of-year recess, Congress raced to provide the drug industry—and the rest of corporate America—a massive tax cut, with breaks for investors, too. Racing to finish their own end-of-year budgets, perhaps, investors poured hundreds of millions into private biotechs, too. If that doesn’t get your blood racing, then how about a look back at ASH, the preeminent hematology conference, and an examination of gene therapy’s pros and cons for hemophilia? We have...
Tags: Law, Republicans, Congress, Senate, Study, America, Trends, Investing, Investment, Tax, Costs, Help, Vc, Report, Gop, Fundraising


Bio Roundup: Trumpcare Flails, Spinraza Sales, Batten OK & More

To judge the first 100 days of a new administration is, as many pundits have pointed out, an odd vestige of history, more convenient than significant. Which is why we’ll start this week’s roundup with our 99-day evaluation of the Trump administration—at least when it comes to healthcare and the life sciences. In healthcare, nothing the administration has done is starker than its failure so far to repeal and replace the Affordable Care Act, a.k.a. Obamacare, perhaps the signature promise o...
Tags: Republicans, Trends, Investment, Vc, Gop, Venture Capital, National, Bill and Melinda Gates Foundation, Biotech, Life Sciences, Trump, Republican House, Batten, National blog main, New York blog main, New York top stories


Bio Roundup: Spinraza Woes, Science March, Baseline Launch & More

Rumblings of a new Obamacare replacement surfaced this week, while scientists and their supporters prepared for Saturday’s—a.k.a. Earth Day’s—nationwide Marches for Science. Our own reporting focused this week on the fallout from high drug prices, with a look at the frustration of families whose children have had trouble gaining access to the first drug ever approved for the rare spinal muscular atrophy. Elsewhere, Google’s cousin Verily finally launched a much ballyhooed health study, No...
Tags: Google, Deals, Trends, Affordable Care Act, Fda, National, Novartis, Abbvie, Roundups, Life Sciences, Amgen, Sanofi, Biogen, Eli Lilly, Regeneron Pharmaceuticals, Gene Therapy


Bio Roundup: CRISPR Drama, Marathon and PhRMA, the Price of Vision & More

News may be coming out of Washington, DC, at a breakneck pace, but concrete plans regarding the future of the nation’s healthcare system, the FDA, and the pharmaceutical industry have been much slower to materialize. The consternation about President Donald Trump’s coming pick for FDA commissioner was palpable this week at the BIO CEO & Investor Conference in New York. Speakers universally panned the idea of dramatically shaking up the FDA or lowering the drug approval bar; one biotech in...
Tags: Deals, Startups, New York, Obamacare, Trends, Merck, Multiple Sclerosis, Washington Dc, Affordable Care Act, Medicare, Alzheimer's, Fda, National, GlaxoSmithKline, Allergan, Donald Trump


Business Leaders Talk Trump’s Impact on Visas, Drug Pricing, Insurance

Perhaps you’ve heard about the inauguration of one Donald J. Trump. Xconomy has been asking prominent members of the national innovation community for their thoughts on the incoming administration and its potential impact on their companies and industries. Here are responses from four business leaders in different cities across Xconomy’s network. Alex Lash, our national biotech editor, traded e-mails with Bob Nelsen, co-founder and managing director at Arch Venture Partners. (Nelsen is ba...
Tags: Startups, Politics, Leadership, Taxes, Obamacare, Entrepreneurship, Immigration, Trends, Insurance, Tax, People, Vc, Policy, Hospitals, Healthcare, Innovation


Drug Maker Who Jacked Up Cost of Baby Medicine 85,000 Percent Still Isn't Sorry

You can lead a drug company to public shame, but you can’t make it feel remorse.Read more...
Tags: Science, Ftc, Mallinckrodt, Drug Pricing, Drug Companies


Trump: The Drug Industry Is 'Getting Away With Murder'

President-elect Donald Trump went after drug makers and sent biotech stocks plummeting after calling the drug industry “disastrous” during his first press conference since the election.Read more...
Tags: Science, Donald Trump, Big Pharma, Drug Pricing


Watching for NIH Innovation in 2017—and Drug Pricing, Trade Deals

With the inauguration of Donald Trump as president on January 20th, the editors asked some of our Xconomists to offer their thoughts on “How could the incoming administration significantly affect your industry?” When I worked in the Reagan Administration, the “Gipper” used to handle questions like this by saying he couldn’t respond to hypothetical questions. That being said, here’s what I’ll be keeping an eye on in Washington in 2017. Thanks to bipartisan support, passage of the 21st Century Cur...
Tags: Startups, Drugs, Washington, Entrepreneurship, Funding, Trends, Reagan, Research and development, Stem Cells, San Diego, Affordable Care Act, Fda, Biotech, Donald Trump, ACA, Life Sciences


How to Lower Drug Prices, Improve Care, and Save Pharma

I recently received a note from a longtime friend who questioned me on the issue of pharma pricing. I answered with the always-reliable alleviating-the-scourge-of-disease-through-the-miracle-of-modern-medicine defense of “free-market pricing.”  My friend, who is not in the pharmaceutical business, responded: The fundamental flaw in your argument centers on the notion that there is any relevance to “market efficiency” in discussing drug pricing.  The entire system of drug delivery operates outsid...
Tags: Startups, Drugs, Entrepreneurship, Trends, Economy, Software, Innovation, Venture Capital, San Diego, Pharmaceuticals, Biotech, Pricing, Life Sciences, Drug Pricing, Boston Xcon, Boulder/Denver Xcon


Pharmaceutical Price Controls Might Be Closer Than You Think

Amid the hue and cry over the Mylan EpiPen pricing debacle, Hillary Clinton unveiled her “Plan to Respond to Unjustified Price Hikes for Long-Available Drugs.”  Clinton’s plan calls for “dedicated oversight to protect consumers.”  To that end she would “convene representatives of federal agencies…to create a dedicated group charged with protecting consumers from outlier price increases.  They would work closely with and be advised by patient advocates, independent non-government experts on drug ...
Tags: Startups, Europe, Drugs, Germany, US, Trends, Eu, Humira, Hillary Clinton, New York Times, Innovation, San Diego, Medicare, Capitol Hill, Pfizer, Allergan


More than a Matter of Appearances: Pharma’s Existential PR Problem

When President Obama forced Pfizer to scrap its proposed $160 billion merger with Allergan, the industry as well as the company emerged as losers in the eyes of the public, despite Pfizer’s credible and constructive position.  As Pfizer CEO Ian Read explained in a recent op-ed piece in The Wall Street Journal: Pfizer has long worked with Congress to make the U.S. tax system more competitive and fair. In the absence of tax reform, we undertook a proposed merger with Allergan PLC in good faith a...
Tags: Deals, Elon Musk, Taxes, Obama, Congress, Drugs, US, Trends, Corporate Strategy, United States, San Diego, Mergers & Acquisitions, Pfizer, Pharmaceuticals, Allergan, Biotech


What’s Ahead for Biotech in 2016: Q&A With BIO Chair Ron Cohen

Biotechnology is a tricky business. We all know the trials and tribulations—and costs—of bringing novel drugs to market. In the past six months or so, a new round of drug pricing upheaval (think Martin Shkreli) and corporate tax “inversions” (think Pfizer-Allergan merger with new headquarters in Ireland) have ignited public debate. Ron Cohen has been on the front lines of all this—wearing a couple of different hats. One is as CEO of Acorda Therapeutics (NASDAQ: ACOR), a biotech company base...
Tags: Health, Deals, New York, Congress, Drugs, Senate, Ipo, San Francisco, Ms, People, Vc, Ireland, House Of Representatives, Jimmy Carter, M&a, Patents


East Coast Bio Roundup: CRISPR, Tessier-Lavigne, Pricing, Spero & More

There was biotech news up and down the East Coast this week. In Boston, all eyes were on the first biotech IPO of the year—and the sector let out a collective sigh when things went well. New York, meanwhile, suffered a tough blow to its life sciences scene, as one of its strongest advocates announced plans to head westward. And in the nation’s capital, executives from Turing Pharmaceuticals and Valeant Pharmaceuticals were blasted by congress at a hearing/political circus on drug pricing. T...
Tags: Deals, Startups, New York, Washington, Stanford, Wall Street, Boston, Merck, Vc, Annapurna, New York Times, Cambridge, Fda, Concussions, East Coast, Roundups


Noted Turd Martin Shkreli Appeared Before Congress, Got in Trouble For Smirking 

Thursday morning, former Turing Pharmaceuticals CEO and current metaphor for the sickness in the soul of America Martin Shkreli was called to testify before the House Committee on Oversight and Government Reform. Shkreli spent the hearing pleading the fifth, but first, he earned a scolding for smirking. Read more...
Tags: America, Martin Shkreli, Turing Pharmaceuticals, Shkreli, House Committee, Drug Pricing, Rep Elijah Fcummings, Turd Martin Shkreli